NEW YORK (TheStreet) -- Shares of AstraZeneca (AZN) are up 2.28% to $72.62 in early market trade and have climbed over 7% percent this week, fueled by speculation of renewed takeover interest from Pfizer (PFE) , following an abortive $118 billion takeover attempt in May, Reuters reports.
But while British takeover rules mean deal talks could be back on the cards as early as August 26, following the ending of the first of a two-stage cooling-off period, many investors and analysts see the year-end as a more likely time for any return, Reuters said.
Must Read: Warren Buffett's 25 Favorite Stocks
TheStreet Ratings team rates ASTRAZENECA PLC as a Buy with a ratings score of B-. TheStreet Ratings Team has this to say about their recommendation:
"We rate ASTRAZENECA PLC (AZN) a BUY. This is driven by multiple strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income."
Highlights from the analysis by TheStreet Ratings Team goes as follows: